A Biopharma Downturn or Return to Trend

Episode Summary

Executive Summary: The episode reviews IQVIA’s view that 2022’s biopharma slowdown was a normalization after pandemic-era spikes, not a structural collapse. Murray Aitken discusses record R&D spending, a still-high pipeline, China’s growing role, the rise of emerging biopharma, persistent trial complexity, concerns about representation, and cautious optimism that AI and digital tools will improve productivity over time.

Main Topics: 2022 biopharma investment reset (Priority: 5/5): IQVIA argues the 35% drop in investment flows into biopharma reflects a return to longer-term trends after exceptional 2020-2021 funding surges during the pandemic. Record R&D spend by large pharma (Priority: 5/5): The 15 largest pharmaceutical companies increased R&D investment to a record level, showing continued strategic commitment to innovation despite broader funding normalization. Pipeline structure and emerging biopharma (Priority: 5/5): Emerging biopharma companies now account for most molecules in clinical development, reflecting stronger venture support and the ability of smaller firms to hold assets longer. Geographic shift toward China (Priority: 4/5): China’s share of the global pipeline has risen sharply, while Europe’s share has declined, signaling a major redistribution of innovation activity. Drug approvals and launches (Priority: 4/5): Novel drug launches fell in 2022, but IQVIA frames the decline as partly driven by fewer COVID-related products, fewer China-origin launches, and fewer accelerated approvals. Clinical trial productivity and complexity (Priority: 5/5): Productivity improved in 2022 largely because fewer subjects were enrolled, while trial complexity remained elevated and success rates remained low. AI, decentralization, and diversity in trials (Priority: 5/5): AI and technology are beginning to influence discovery and development, but real-world impact is still emerging; the discussion also highlights troubling declines in Black and Hispanic trial representation.

Key Arguments: The 2020 and 2021 funding environment was exceptional, and 2022 largely represented a return to baseline rather than a crisis. Large pharma is prioritizing R&D more than ever, even as external capital markets and biotech ecosystems keep early-stage companies independent longer. The pipeline is robust, with more than 6,000 molecules in active development, indicating substantial scientific activity despite funding normalization. China is becoming a more important global innovation hub because of government support, regulatory modernization, and a more attractive market for innovative medicines. Emerging biopharma now drives most of the pipeline because venture capital, academic spinouts, and niche indications favor smaller, more flexible companies. The decline in novel approvals is partly explained by fewer COVID products, fewer China launches, and fewer FDA accelerated approvals, not necessarily a collapse in productivity. Clinical development productivity improved in 2022 mainly because trial enrollment volumes dropped after unusually large pandemic-era studies. A falling composite success rate reflects greater scientific risk-taking, while operational risk should be reduced through decentralization, novel trial designs, real-world data, and AI. AI is showing promise in discovery, site selection, and recruitment, but industry-wide impact is still early and not yet visible in aggregate metrics. Despite attention to diversity, trial representation for Black and Hispanic patients declined in publicly reported data, though lagged reporting may mean the full effect of current efforts is not yet visible.

Data Points: Investment flows into biopharma: 35% decline in 2022 - IQVIA characterized this as a return to trend after pandemic-era highs. Excess funding in 2020-2021: About $120 billion - Estimated amount above expected levels during the exceptional pandemic years. R&D spending by 15 largest pharma companies: $138 billion - Record level in 2022, described as 19% of revenue. Share of pipeline held by emerging biopharma: About two-thirds - Emerging biopharma companies account for roughly two-thirds of molecules in clinical development. Total molecules in active development: Over 6,000 - Industry-wide pipeline size described as at an all-time high level. China’s share of global pipeline: 15% in 2022, up from 6% five years earlier - Shows rapid growth in China’s role in innovation and clinical development. Europe’s share of global pipeline: 23% in 2022, down from 27% five years earlier - Indicates a relative decline in Europe’s share of innovation activity. Novel active substances launched globally: 64 in 2022 - Down from 93 in 2021, but still strong by pre-pandemic standards. Novel active substances launched globally in 2021: 93 - Used as comparison year for the decline in 2022. Historical launch benchmark: 40s to 50s in pre-pandemic years; 60 in 2018 - Demonstrates that 64 launches in 2022 remained above earlier norms. Median time from patent to approval: More than 11 years - Illustrates the long development cycle despite technology gains. Composite success rate in 2022: 6.3% - Reached a low point in clinical development success rates. AI-originated molecules in clinical development: At least 19 - Molecules tracked as originating from AI platforms in discovery research.

Pivotal Quotes: "In 2022, we saw a return to trend, essentially." — Murray Aitken: Explaining why the drop in biopharma investment should be seen as normalization rather than a structural downturn. "They’re swinging for the fences, I would say, in terms of the level of scientific risk that’s being taken." — Murray Aitken: Describing the large pharma commitment to high-risk, high-reward R&D investment. "There is a lot of hope that it will result in faster trials." — Murray Aitken: Discussing the expected impact of technology adoption on clinical development speed and efficiency.

Implications: The sector remains strong but is shifting geographically and structurally. Expect more China-linked innovation, continued dominance of emerging biopharma, and growing use of AI/tech to reduce operational friction, while diversity gains in trials remain an urgent unresolved challenge.